- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05454930
Effect of Commute Traffic on Vascular Function
8. juli 2022 opdateret af: Joel Daniel Kaufman, University of Washington
The investigators will assess the vascular effects of riding in a car in heavily trafficked roadways, and whether filtering the car's air reduces those effects.
Studieoversigt
Detaljeret beskrivelse
In this double-blind, crossover trial, randomized to order, recruited participants will be screened and then will accompany the study team on three typical commutes on separate days with sufficient washout (i.e., three weeks) between drives.
One day this will occur with an effective filter system in the vehicle and the other two days without effective filtration; ineffective filtration is the most typical actual vehicle condition.
Subjects will be unaware of the filtration conditions of the commute on that day.
Each subject's experimental sessions will occur at the same time of day and will be separated by at least 21 days.
The two sessions (either filtered air or traffic-derived entrained air) will be 120 minutes in duration and will encompass routes on heavily traveled roadways in the Seattle area.
Before subjects begin the commute trials, they will go through the consent process and a series of screening tests.
The study investigators will assess a series of measures regarding vascular function before and after each drive.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
16
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98195
- University of Washington Medical Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 49 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- healthy
Exclusion Criteria:
- asthma,
- high blood pressure,
- diabetes,
- high cholesterol,
- other chronic conditions requiring ongoing medical care.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: Typical Commute
Participants spend two hours in automobile, on heavily trafficked roadways, without active filtration of air pollutants
|
|
|
Andet: Typical Commute, Filtered Air
Participants spend two hours in automobile, on heavily trafficked roadways, with active filtration of air pollutants
|
The vehicle is fitted with a (High-Efficiency Particulate Absorbing, HEPA) filter device incorporating a charcoal filter, as well as an augmented cabin filter
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Brachial Artery Diameter from Pre-Drive to Post-Drive
Tidsramme: 30 minutes before 120 minute driving session; 30 minutes post driving session
|
Ultrasound assessment of brachial artery diameter, in millimeters.
|
30 minutes before 120 minute driving session; 30 minutes post driving session
|
|
Change in Blood Pressure from Pre-Drive to During-Drive and Post-drive
Tidsramme: 10 minutes before driving session; 15, 30, 45, 60, 75, 90, 100, 120 minutes following start of (120 minute) driving session; 10 minutes, 1.5 hours, 3.5 hours, 6 hours, 24 hours after end of driving session.
|
systolic and diastolic blood pressure measured in mmHg
|
10 minutes before driving session; 15, 30, 45, 60, 75, 90, 100, 120 minutes following start of (120 minute) driving session; 10 minutes, 1.5 hours, 3.5 hours, 6 hours, 24 hours after end of driving session.
|
|
Change in Retinal Arteriolar Diameter from Pre-Drive to Post-Drive
Tidsramme: 30 minutes before 120 minute driving session; 30 minutes post driving session
|
measured by retinal photography, image analysis, in micrometers
|
30 minutes before 120 minute driving session; 30 minutes post driving session
|
|
Gene Expression and DNA methylation
Tidsramme: 30 minutes before 120 minute driving session; 30 minutes, 5 hour, and 24 hours post-driving session
|
analysis in circulating mononuclear cells; determined via fold change in abundance
|
30 minutes before 120 minute driving session; 30 minutes, 5 hour, and 24 hours post-driving session
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
circulating stress hormone
Tidsramme: 30 minutes before 120 minute driving session; 5 hour and 24 hours post-driving session
|
cortisol by chemiluminescence (ng/mL)
|
30 minutes before 120 minute driving session; 5 hour and 24 hours post-driving session
|
|
complete blood count with differential
Tidsramme: 30 minutes before 120 minute driving session; 5 hour and 24 hours post-driving session
|
laboratory values for hematologic indices (cells/uL)
|
30 minutes before 120 minute driving session; 5 hour and 24 hours post-driving session
|
|
inflammatory marker interleukin-6
Tidsramme: 30 minutes before 120 minute driving session; 5 hour and 24 hours post-driving session
|
interleukin-6 determined by chemiluminescence (pg/mL)
|
30 minutes before 120 minute driving session; 5 hour and 24 hours post-driving session
|
|
inflammatory marker c-reactive protein
Tidsramme: 30 minutes before 120 minute driving session; 5 hour and 24 hours post-driving session
|
C-reactive protein by immunoturbidimetry (ug/mL)
|
30 minutes before 120 minute driving session; 5 hour and 24 hours post-driving session
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Joel Kaufman, MD, University of Washington
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. januar 2015
Primær færdiggørelse (Faktiske)
1. juli 2016
Studieafslutning (Faktiske)
1. december 2016
Datoer for studieregistrering
Først indsendt
31. juli 2015
Først indsendt, der opfyldte QC-kriterier
8. juli 2022
Først opslået (Faktiske)
12. juli 2022
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
12. juli 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
8. juli 2022
Sidst verificeret
1. juli 2022
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STUDY00001196
- K24ES013195 (U.S. NIH-bevilling/kontrakt)
- RD-83479601 (Andet bevillings-/finansieringsnummer: US Environmental Protection Agency STAR)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hjerte-kar-sygdomme
-
Ottawa Hospital Research InstituteAfsluttetStress | Crisis Resource Management (CRM) færdigheder | Advanced Cardiovascular Life Support (ACLS) færdighederCanada
Kliniske forsøg med Filtered Air
-
University of ToyamaNational Cancer Center, Korea; Samsung Medical Center; Seoul National University... og andre samarbejdspartnereAfsluttetSygdom af bugspytkirtel eller periampullære læsionerJapan
-
Massachusetts General HospitalAfsluttetPerinatal asfyksi | Asphyxia Neonatorum | Fødselsasfyksi
-
Boston Medical CenterGunze LimitedTrukket tilbageLuftlækage fra lungenForenede Stater
-
AIRNA CorporationRekrutteringAlpha 1 Antitrypsin mangelDet Forenede Kongerige, Australien, Georgien
-
Nimbic Systems, LLCAfsluttet
-
Riphah International UniversityAfsluttet
-
i-SENS, Inc.Integrated Medical DevelopmentRekrutteringType 1 diabetes mellitusForenede Stater
-
CIBA VISIONAfsluttetPresbyopi | Astigmatisme | Nærsynethed
-
air up GmbHCitruslabsAfsluttet
-
ResMedAfsluttetSøvnforstyrret vejrtrækningForenede Stater